Leerink Partners Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $23.00

Keros Therapeutics (NASDAQ:KROS) had its target price trimmed by Leerink Partners from $30.00 to $23.00 in a report released on Tuesday morning, MarketBeat.com reports. The brokerage currently has an outperform rating on the stock.

Several other brokerages have also recently weighed in on KROS. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Keros Therapeutics in a report on Tuesday. Wall Street Zen lowered shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Zacks Research cut shares of Keros Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 29th. Finally, Weiss Ratings cut shares of Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 15th. Four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $20.50.

Keros Therapeutics Stock Performance

NASDAQ KROS opened at $10.65 on Tuesday. The stock has a fifty day moving average of $10.62 and a 200-day moving average of $12.40. The stock has a market capitalization of $211.19 million, a P/E ratio of -2.88 and a beta of 0.99. Keros Therapeutics has a 52 week low of $9.69 and a 52 week high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. Equities research analysts forecast that Keros Therapeutics will post -4.96 earnings per share for the current fiscal year.

Insider Transactions at Keros Therapeutics

In related news, Director Julius Knowles sold 2,625 shares of Keros Therapeutics stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $10.73, for a total transaction of $28,166.25. Following the completion of the sale, the director directly owned 10,958 shares of the company’s stock, valued at $117,579.34. The trade was a 19.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nima Farzan sold 2,625 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $10.73, for a total value of $28,166.25. Following the completion of the sale, the director owned 9,767 shares of the company’s stock, valued at $104,799.91. This represents a 21.18% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 8,425 shares of company stock worth $89,994 in the last three months. Insiders own 12.60% of the company’s stock.

Hedge Funds Weigh In On Keros Therapeutics

Several institutional investors have recently modified their holdings of KROS. Renaissance Technologies LLC boosted its stake in Keros Therapeutics by 282.5% during the 4th quarter. Renaissance Technologies LLC now owns 591,686 shares of the company’s stock worth $12,047,000 after acquiring an additional 436,986 shares during the last quarter. Canada Pension Plan Investment Board acquired a new position in Keros Therapeutics during the second quarter valued at approximately $4,251,000. Caption Management LLC increased its stake in Keros Therapeutics by 114.1% in the second quarter. Caption Management LLC now owns 36,078 shares of the company’s stock valued at $482,000 after purchasing an additional 291,997 shares in the last quarter. Qube Research & Technologies Ltd increased its stake in Keros Therapeutics by 683.7% in the third quarter. Qube Research & Technologies Ltd now owns 303,122 shares of the company’s stock valued at $4,795,000 after purchasing an additional 264,445 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in Keros Therapeutics by 453.9% in the first quarter. Dimensional Fund Advisors LP now owns 321,360 shares of the company’s stock worth $3,547,000 after purchasing an additional 263,347 shares during the period. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Keros Therapeutics

Here are the key news stories impacting Keros Therapeutics this week:

• Positive Sentiment: Wells Fargo initiated a Buy rating on Keros Therapeutics, adding a new bullish opinion that may be helping investor sentiment. Wells Fargo Issues a Buy Rating on Keros Therapeutics
• Positive Sentiment: HC Wainwright maintained its Buy rating and $20 price target while raising its FY2026 EPS forecast to a loss of $4.62 from a loss of $5.12. The improved estimate is favorable relative to the firm’s prior outlook and supports the broader bullish analyst view. HC Wainwright Keros Therapeutics analyst estimates
• Neutral Sentiment: Analysts continue to describe Keros Therapeutics as attractive among healthcare stocks, but the company remains unprofitable, with a negative earnings outlook and substantial dependence on future clinical and commercial progress. Analysts Are Bullish on Top Healthcare Stocks
• Negative Sentiment: HC Wainwright lowered its Q4 2026 EPS forecast to a loss of $1.49 from $1.33 and reduced estimates for FY2027 through FY2030. The cuts imply larger expected losses in those years, despite the unchanged Buy rating and $20 target. HC Wainwright revised Keros Therapeutics earnings estimates
• Negative Sentiment: Leerink Partners lowered its Keros Therapeutics price target to $23. The target remains well above recent trading levels, but the reduction signals a more cautious valuation assessment. Leerink Partners Lowers Keros Therapeutics Price Target

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-?) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.